Frequently asked questions
The COVID-19 pandemic positively impacted the global liraglutide injection market. In patients with COVID-19, diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes, including a higher risk of terminal illness or death. Liraglutide, like glucagon, is a peptide1 (GLP1) receptor, an agonist. As a result, GLP-1RAs have been identified as potential candidates for treating COVID-19 infection patients with or without type 2 diabetes, and they are excellent antidiabetic (glucose-low
North America accounted for the most heightened share in the global liraglutide injection market.
The rising prevalence of type II diabetes, the growing geriatric population, and the increasing preference for weight-loss therapies are driving the growth of the global liraglutide injection market.
The type II segment had a major share in the global market in 2021.
The weight loss segment had a major share in the global market.